How Pluryal Silk and Densify Are Healing Skin from Within – from Lecheng’s Qiyan Hospital in Hainan

Before I started working in aesthetic medicine, I never fully understood the difference between filling a line and truly healing the skin. But after years of watching patients come back with stretched, overfilled faces and tissues that looked more “done” than rejuvenated, I began searching alternatives deeper than the draw of hyaluronic acid (HA). So when news reached us at Lecheng that Qiyan Hospital had introduced Pluryal® injectable polynuclear fillers, I confess my excitement was tempered by a healthy dose of professional skepticism. Yet the more I learned about the science of polynucleotides (PN), the more I realized this wasn’t just another filler. It was a paradigm shift.

Pluryal, known in Chinese markets under the elegant brand name 佰洛雅, is a high-end European medical aesthetics brand with deep roots. The brand began its journey as early as 1998, initially distributing medical aesthetic products before launching its own Mesoline line in 2009, which was soon followed by hyaluronic acid fillers and a skincare range in 2015. Headquartered in the Grand Duchy of Luxembourg, Pluryal remains a family-owned business now managed by four passionate siblings — a rare continuity in an industry fueled by venture capital and quarterly reports. Today, Pluryal treatments are available in over 70 countries across five continents, and all products are manufactured in compliance with EU regulations and carry the CE mark, as Class III medical devices. More importantly, every product line undergoes rigorous clinical testing and is produced under ISO 13485 and ISO 22716 standards, with individual visual inspection before release — a level of quality control that, speaking as a practitioner, gives me genuine peace of mind.

Pluryal’s portfolio is built around highly purified polynucleotides extracted from salmon sperm — a raw material that sounds unusual at first but makes perfect biological sense. Human and salmon DNA share approximately 98% structural homology, which means the molecules are recognized by human tissues as familiar rather than foreign. This biocompatibility significantly reduces the risk of allergic reactions and inflammatory responses, a claim supported by practical clinical data. The purification process uses Pluryal’s proprietary HPN technology, which extracts DNA chains of different lengths and subjects them to high-temperature sterilization, forming a unique three-dimensional support structure once injected. As a result, PN functions less like a static filler and more like a biological scaffold that actively works with the body’s own repair mechanisms.

Understanding the science is one thing. Understanding how these products translate into visible improvements for real patients is another. Thanks to Lecheng’s “pilot first” policies — authorized by the State Council — Pluryal has now gained expedited import approval into China, as a clinical-need import medical device. Two products have officially landed at the Qiyan Stem Cell Anti-Aging Hospital in the Boao Lecheng International Medical Tourism Pilot Zone, where my team and I are now preparing to administer the very first injections in mainland China.

Before I break down each product, let me clarify what makes PN so fundamentally different from what the market is used to. Traditional HA fillers work by adding volume — essentially, putting “stuff” into the skin to plump it up. They correct wrinkles, restore facial contours, and improve hydration, but they do so passively. Once the HA degrades, the volume goes with it. Pluryal, by contrast, functions as a biostimulator. Its active ingredient, PN, does not merely occupy space. It binds to skin fibroblasts and activates them, encouraging the production of collagen, elastin, and other components of the extracellular matrix. It also absorbs water to retain deep hydration, reduces inflammation through its antioxidant properties, and even promotes new blood vessel formation via angiogenic signals. In short, it heals rather than just fills. This is what makes Pluryal a true bio-regenerative therapy rather than a passive dermal filler.

So what exactly are we offering at Lecheng?

Pluryal® SILK — marketed as “silk needle” for its exceptionally smooth texture — is a pure PN injectable designed specifically for delicate areas of the face and body: under-eyes, perioral region, neck, decolletage, and hands. Its clinical indications include improving skin tone and radiance, reducing fine lines and dark circles, minimizing enlarged pores, lightening postpartum stretch marks, and enhancing overall skin elasticity, smoothness and moisture balance. What I find particularly compelling about Silk is its global track record: over 166,000 units have been used worldwide, with zero product-related serious adverse reactions reported. And it also carries a unique distinction — Silk is the world’s first CE-certified PN formulation exclusively approved for use around the eyes, which speaks volumes about its safety profile for the most sensitive skin areas.

Pluryal® DENSIFY — often called the “densifying needle” — is a hybrid formulation that combines 50% PN with 50% non-cross-linked HA, plus mannitol as an added stabilizer, in a precise 1:1 ratio. This unique composition creates a synergistic effect where PN stimulates deeper collagen remodeling while HA provides immediate hydration and surface smoothing. The addition of mannitol serves a dual purpose: it acts as a free radical scavenger to reduce oxidative stress, and it helps stabilize HA against enzymatic degradation, thereby prolonging the treatment’s effects. From a practical perspective, Densify is intended for broader use across the face, neck, chest and even deeper wrinkles and scars, and is particularly effective for aging skin requiring both lift and firmness. With over 160,000 units used globally under post-market surveillance, the safety data remains robust — again, no serious product-related adverse events have been recorded.

If you’re weighing these two options, here’s a clinical rule of thumb I’ve adopted: choose Silk for targeted refinement of delicate areas like the under-eyes, perioral lines, or hands; choose Densify for global facial rejuvenation that addresses issues such as skin laxity, texture irregularities, deep wrinkles and pigmentation over larger surface areas. And because both products are fully biodegradable and non-immunogenic, they integrate naturally into the body without leaving unwanted residues. Pluryal’s entire series is sterile, ready-to-use and preservative-free, in line with the “clean beauty” principles that many of my patients now prioritize.

Many patients ask me, “If I’ve already used HA fillers or regular mesotherapy serums, why should I consider Pluryal?” The answer lies in the difference between passive and active regeneration. Traditional HA-based fillers correct wrinkles by adding volume and provide temporary surface-level hydration. Pluryal, on the other hand, is a true biostimulator — it works on the skin’s own repair system to produce long-lasting, natural results without the artificial “puffed” appearance. Unlike conventional skin boosters that focus primarily on HA, Pluryal’s PN component actively promotes collagen and elastin synthesis at the cellular level, complementing and amplifying the skin’s natural ability to regenerate. Several independent studies have confirmed PN’s wound-healing, anti-inflammatory and angiogenic effects, making it a more holistic solution.

Another key difference lies in product formulation complexity. While many PN-based products on the market focus on a single active ingredient, Pluryal offers a blended approach — adding in HA, mannitol, and even peptides in certain lines to create synergistic effects that target multiple skin concerns simultaneously. This multi-modal approach is, in my experience, more clinically versatile. For patients with multiple aesthetic concerns — dryness, laxity, wrinkles and uneven tone — Pluryal can address them all in fewer sessions, which improves adherence and overall satisfaction.

Aesthetic claims are abundant, but real evidence is rarer. However, Pluryal’s clinical record is one I trust, not just because of marketing materials, but because of its CE certification as a Class III medical device under the EU MDR directive, as well as its ISO 13485 production compliance — standards that demand demonstrable evidence of safety and performance. Although I am not a researcher by training, the growing body of peer-reviewed literature on PN-based tissue repair — including studies on knee osteoarthritis and dermatological applications — has shaped my confidence in recommending these products to patients. And speaking from practical experience, the visible results I have observed with my own patients repeatedly bear out the science. In patients treated with Pluryal Silk, I routinely see improvements in skin radiance and reduced fine lines within two to four weeks — far faster than many regenerative treatments, which can take months to show results.

Readily available award data is limited, but the product’s global expansion — to over 70 countries — speaks for itself. More telling still is that at aesthetic conferences across Europe and Asia, Pluryal is increasingly mentioned in the same breath as Rejuran, another leading PN product. But unlike the latter, Pluryal offers a broader blend of active ingredients, making it a more versatile choice for clinicians. In my practice, this versatility has translated directly into better patient outcomes and fewer touch-up sessions.

Lecheng’s role here is also pivotal. By facilitating the import of pre-approved medical devices not yet cleared in mainland China, Lecheng allows us to offer treatments that would otherwise be unavailable for years. As a result, at Qiyan Hospital — a world-class, international-grade facility accredited as a Class III general hospital — my colleagues and I can now deliver Pluryal’s advanced PN and PN-HA technologies to our patients, using the most up-to-date, evidence-based protocols. It’s a privilege to practice at the frontier of aesthetic medicine, but also a humbling reminder that with such access comes responsibility — to stay informed, to educate transparently, and to treat every patient as an individual first.

Let me be transparent about something: Pluryal is a powerful medical device, not a cosmetic pampering session. In China, it has been approved as an imported Class III medical device, which means it must be administered only by registered physicians who have been specifically trained in its protocols. At our Lecheng facility, every Pluryal treatment is conducted by board-certified aesthetic doctors who understand the anatomy of the face in depth — not beauty therapists. Prior to injection, we conduct full skin assessments, confirm patient medical history (including allergies to fish products — a small but important precaution, as PN is salmon-derived), and set realistic expectations. The treatment itself takes about 15 to 30 minutes, involves minimal downtime, and is almost painless. Some redness or slight swelling may appear at injection sites, but these typically resolve within 24 to 48 hours.

That said, Pluryal is a biostimulator, not a drug. Its effects accumulate over time, typically reaching optimal levels around three months post-treatment and lasting up to 12 months. I generally recommend an initial series of three sessions spaced three to four weeks apart, followed by maintenance treatments every three to six months depending on the patient’s age, lifestyle, and aesthetic goals. Smoking, excessive sun exposure, and poor skincare practices can shorten the interval between maintenance sessions — something I always discuss honestly with my patients.

Pluryal is contraindicated in acute inflammatory skin conditions, active infections at the injection sites, known bleeding disorders, or during pregnancy and lactation. Patients with fish allergies should also exercise caution. At Lecheng, we adhere strictly to these contraindications, because no aesthetic result is worth compromising patient safety.